Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Bioxcel Therapeutics, Inc. (BTAI) since 2018 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Bioxcel Therapeutics, Inc.. Table 2 shows the detailed insider transactions. This company's CIK number is 1720893.
Total stock buying since 2018: $242,339.
Total stock sales since 2018: $75,566,276.
Total stock option exercises since 2018: $382,667.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2025 | 0 | $0 | 0 | $0 | 14,261 | $0 |
| 2024 | 0 | $0 | 1,481,872 | $930,069 | 88,924 | $0 |
| 2023 | 0 | $0 | 342,362 | $7,725,966 | 327,566 | $110,581 |
| 2022 | 0 | $0 | 120,000 | $2,087,700 | 120,000 | $49,199 |
| 2021 | 0 | $0 | 1,991,750 | $63,517,916 | 68,750 | $179,837 |
| 2020 | 0 | $0 | 25,000 | $1,304,625 | 105,000 | $43,050 |
| 2019 | 14,957 | $131,541 | 0 | $0 | 0 | $0 |
| 2018 | 22,152 | $110,798 | 0 | $0 | 0 | $0 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2025-08 | 0 | $0 | 0 | $0 | 1,693 | $0 |
| 2025-07 | 0 | $0 | 0 | $0 | 2,943 | $0 |
| 2025-06 | 0 | $0 | 0 | $0 | 2,279 | $0 |
| 2025-05 | 0 | $0 | 0 | $0 | 1,693 | $0 |
| 2025-04 | 0 | $0 | 0 | $0 | 1,693 | $0 |
| 2025-03 | 0 | $0 | 0 | $0 | 2,267 | $0 |
| 2025-02 | 0 | $0 | 0 | $0 | 1,693 | $0 |
| 2024-12 | 0 | $0 | 4,719 | $1,700 | 9,880 | $0 |
| 2024-11 | 0 | $0 | 0 | $0 | 27,089 | $0 |
| 2024-10 | 0 | $0 | 33,041 | $18,170 | 0 | $0 |
| 2024-09 | 0 | $0 | 3,391 | $2,337 | 10,632 | $0 |
| 2024-06 | 0 | $0 | 1,431,132 | $882,668 | 10,629 | $0 |
| 2024-04 | 0 | $0 | 9,589 | $25,194 | 0 | $0 |
| 2024-03 | 0 | $0 | 0 | $0 | 30,694 | $0 |
| 2023-12 | 0 | $0 | 0 | $0 | 4,693 | $0 |
| 2023-09 | 0 | $0 | 0 | $0 | 4,694 | $0 |
| 2023-06 | 0 | $0 | 60,000 | $1,277,640 | 64,693 | $24,600 |
| 2023-05 | 0 | $0 | 13,285 | $352,270 | 25,000 | $0 |
| 2023-04 | 0 | $0 | 60,000 | $1,039,200 | 60,000 | $24,600 |
| 2023-03 | 0 | $0 | 69,364 | $1,332,698 | 78,773 | $24,600 |
| 2023-01 | 0 | $0 | 139,713 | $3,724,158 | 89,713 | $36,781 |
| 2022-12 | 0 | $0 | 60,000 | $1,187,700 | 60,000 | $24,600 |
| 2022-11 | 0 | $0 | 60,000 | $900,000 | 60,000 | $24,599 |
| 2021-06 | 0 | $0 | 1,893,000 | $58,357,404 | 0 | $0 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2025-08-31 | Mack David J. | Option Ex | 1,693 | .00 | 0 |
| 2025-07-31 | Mack David J. | Option Ex | 1,693 | .00 | 0 |
| 2025-07-22 | Rodriguez Javier (See Remarks) | Option Ex | 625 | .00 | 0 |
| 2025-07-22 | Steinhart Richard I (Chief Financial Officer) | Option Ex | 625 | .00 | 0 |
| 2025-06-30 | Mack David J. | Option Ex | 1,693 | .00 | 0 |
| 2025-06-15 | Rodriguez Javier (See Remarks) | Option Ex | 35 | .00 | 0 |
| 2025-06-15 | Mehta Vimal (CEO and President) | Option Ex | 219 | .00 | 0 |
| 2025-06-15 | Yocca Frank (Chief Scientific Officer) | Option Ex | 35 | .00 | 0 |
| 2025-06-15 | Steinhart Richard I (Chief Financial Officer) | Option Ex | 35 | .00 | 0 |
| 2025-06-14 | Rodriguez Javier (See Remarks) | Option Ex | 33 | .00 | 0 |
| 2025-06-14 | Mehta Vimal (CEO and President) | Option Ex | 163 | .00 | 0 |
| 2025-06-14 | Yocca Frank (Chief Scientific Officer) | Option Ex | 33 | .00 | 0 |
| 2025-06-14 | Steinhart Richard I (Chief Financial Officer) | Option Ex | 33 | .00 | 0 |
| 2025-05-31 | Mack David J. | Option Ex | 1,693 | .00 | 0 |
| 2025-04-30 | Mack David J. | Option Ex | 1,693 | .00 | 0 |
| 2025-03-31 | Mack David J. | Option Ex | 1,693 | .00 | 0 |
| 2025-03-15 | Rodriguez Javier (See Remarks) | Option Ex | 34 | .00 | 0 |
| 2025-03-15 | Mehta Vimal (CEO and President) | Option Ex | 217 | .00 | 0 |
| 2025-03-15 | Yocca Frank (Chief Scientific Officer) | Option Ex | 34 | .00 | 0 |
| 2025-03-15 | Steinhart Richard I (Chief Financial Officer) | Option Ex | 34 | .00 | 0 |
| 2025-03-14 | Rodriguez Javier (See Remarks) | Option Ex | 31 | .00 | 0 |
| 2025-03-14 | Mehta Vimal (CEO and President) | Option Ex | 162 | .00 | 0 |
| 2025-03-14 | Yocca Frank (Chief Scientific Officer) | Option Ex | 31 | .00 | 0 |
| 2025-03-14 | Steinhart Richard I (Chief Financial Officer) | Option Ex | 31 | .00 | 0 |
| 2025-02-28 | Mack David J. | Option Ex | 1,693 | .00 | 0 |
| 2024-12-16 | Rodriguez Javier (See Remarks) | Sale | 430 | .36 | 153 |
| 2024-12-16 | Mehta Vimal (CEO and President) | Sale | 3,117 | .36 | 1,131 |
| 2024-12-16 | Yocca Frank (Chief Scientific Officer) | Sale | 430 | .35 | 151 |
| 2024-12-16 | O'neill Vincent (See Remarks) | Sale | 165 | .35 | 58 |
| 2024-12-16 | Steinhart Richard I (Chief Financial Officer) | Sale | 577 | .36 | 207 |
| 2024-12-15 | Rodriguez Javier (See Remarks) | Option Ex | 562 | .00 | 0 |
| 2024-12-15 | Mehta Vimal (CEO and President) | Option Ex | 3,500 | .00 | 0 |
| 2024-12-15 | Yocca Frank (Chief Scientific Officer) | Option Ex | 562 | .00 | 0 |
| 2024-12-15 | Steinhart Richard I (Chief Financial Officer) | Option Ex | 562 | .00 | 0 |
| 2024-12-14 | Rodriguez Javier (See Remarks) | Option Ex | 521 | .00 | 0 |
| 2024-12-14 | Mehta Vimal (CEO and President) | Option Ex | 2,610 | .00 | 0 |
| 2024-12-14 | Yocca Frank (Chief Scientific Officer) | Option Ex | 521 | .00 | 0 |
| 2024-12-14 | O'neill Vincent (See Remarks) | Option Ex | 521 | .00 | 0 |
| 2024-12-14 | Steinhart Richard I (Chief Financial Officer) | Option Ex | 521 | .00 | 0 |
| 2024-11-30 | Mack David J. | Option Ex | 27,089 | .00 | 0 |
| 2024-10-03 | Rodriguez Javier (See Remarks) | Sale | 6,863 | .55 | 3,774 |
| 2024-10-03 | Wiley Matthew T. (Chief Commercial Officer) | Sale | 6,272 | .55 | 3,449 |
| 2024-10-03 | Yocca Frank (Chief Scientific Officer) | Sale | 7,175 | .55 | 3,946 |
| 2024-10-03 | O'neill Vincent (See Remarks) | Sale | 5,556 | .55 | 3,055 |
| 2024-10-03 | Steinhart Richard I (Chief Financial Officer) | Sale | 7,175 | .55 | 3,946 |
| 2024-09-16 | Rodriguez Javier (See Remarks) | Sale | 345 | .69 | 238 |
| 2024-09-16 | Wiley Matthew T. (Chief Commercial Officer) | Sale | 215 | .69 | 148 |
| 2024-09-16 | Mehta Vimal (CEO and President) | Sale | 1,982 | .69 | 1,367 |
| 2024-09-16 | Yocca Frank (Chief Scientific Officer) | Sale | 355 | .69 | 244 |
| 2024-09-16 | O'neill Vincent (See Remarks) | Sale | 138 | .69 | 95 |
| 2024-09-16 | Steinhart Richard I (Chief Financial Officer) | Sale | 356 | .69 | 245 |
| 2024-09-15 | Rodriguez Javier (See Remarks) | Option Ex | 563 | .00 | 0 |
| 2024-09-15 | Wiley Matthew T. (Chief Commercial Officer) | Option Ex | 750 | .00 | 0 |
| 2024-09-15 | Mehta Vimal (CEO and President) | Option Ex | 3,500 | .00 | 0 |
| 2024-09-15 | Yocca Frank (Chief Scientific Officer) | Option Ex | 563 | .00 | 0 |
| 2024-09-15 | Steinhart Richard I (Chief Financial Officer) | Option Ex | 563 | .00 | 0 |
| 2024-09-14 | Rodriguez Javier (See Remarks) | Option Ex | 521 | .00 | 0 |
| 2024-09-14 | Mehta Vimal (CEO and President) | Option Ex | 2,609 | .00 | 0 |
| 2024-09-14 | Yocca Frank (Chief Scientific Officer) | Option Ex | 521 | .00 | 0 |
| 2024-09-14 | O'neill Vincent (See Remarks) | Option Ex | 521 | .00 | 0 |
| 2024-09-14 | Steinhart Richard I (Chief Financial Officer) | Option Ex | 521 | .00 | 0 |
| 2024-06-17 | Rodriguez Javier (See Remarks) | Sale | 361 | 1.26 | 455 |
| 2024-06-17 | Wiley Matthew T. (Chief Commercial Officer) | Sale | 244 | 1.26 | 308 |
| 2024-06-17 | Mehta Vimal (CEO and President) | Sale | 2,134 | 1.28 | 2,740 |
| 2024-06-17 | Yocca Frank (Chief Scientific Officer) | Sale | 372 | 1.28 | 476 |
| 2024-06-17 | O'neill Vincent (See Remarks) | Sale | 155 | 1.28 | 199 |
| 2024-06-17 | Steinhart Richard I (Chief Financial Officer) | Sale | 372 | 1.26 | 469 |
| 2024-06-15 | Rodriguez Javier (See Remarks) | Option Ex | 562 | .00 | 0 |
| 2024-06-15 | Wiley Matthew T. (Chief Commercial Officer) | Option Ex | 750 | .00 | 0 |
| 2024-06-15 | Mehta Vimal (CEO and President) | Option Ex | 3,500 | .00 | 0 |
| 2024-06-15 | Yocca Frank (Chief Scientific Officer) | Option Ex | 562 | .00 | 0 |
| 2024-06-15 | Steinhart Richard I (Chief Financial Officer) | Option Ex | 562 | .00 | 0 |
| 2024-06-14 | Rodriguez Javier (See Remarks) | Option Ex | 521 | .00 | 0 |
| 2024-06-14 | Mehta Vimal (CEO and President) | Option Ex | 2,609 | .00 | 0 |
| 2024-06-14 | Yocca Frank (Chief Scientific Officer) | Option Ex | 521 | .00 | 0 |
| 2024-06-14 | O'neill Vincent (See Remarks) | Option Ex | 521 | .00 | 0 |
| 2024-06-14 | Steinhart Richard I (Chief Financial Officer) | Option Ex | 521 | .00 | 0 |
| 2024-06-05 | Bioxcel Llc | Sale | 409,136 | .79 | 324,035 |
| 2024-06-04 | Bioxcel Llc | Sale | 1,018,358 | .54 | 553,986 |
| 2024-04-04 | Rodriguez Javier (See Remarks) | Sale | 1,012 | 2.64 | 2,667 |
| 2024-04-04 | Wiley Matthew T. (CHIEF COMMERCIAL OFFICER) | Sale | 1,008 | 2.63 | 2,656 |
| 2024-04-04 | Mehta Vimal (CEO and President) | Sale | 5,268 | 2.62 | 13,812 |
| 2024-04-04 | Yocca Frank (Chief Scientific Officer) | Sale | 1,067 | 2.63 | 2,811 |
| 2024-04-04 | O'neill Vincent (See Remarks) | Sale | 165 | 2.62 | 432 |
| 2024-04-04 | Steinhart Richard I (Chief Financial Officer) | Sale | 1,069 | 2.63 | 2,816 |
| 2024-03-15 | Rodriguez Javier (See Remarks) | Option Ex | 2,250 | .00 | 0 |
| 2024-03-15 | Wiley Matthew T. (CHIEF COMMERCIAL OFFICER) | Option Ex | 3,000 | .00 | 0 |
| 2024-03-15 | Mehta Vimal (CEO and President) | Option Ex | 14,000 | .00 | 0 |
| 2024-03-15 | Yocca Frank (Chief Scientific Officer) | Option Ex | 2,250 | .00 | 0 |
| 2024-03-15 | O'neill Vincent (See Remarks) | Option Ex | 2,250 | .00 | 0 |
| 2024-03-15 | Steinhart Richard I (Chief Financial Officer) | Option Ex | 2,250 | .00 | 0 |
| 2024-03-14 | Rodriguez Javier (See Remarks) | Option Ex | 521 | .00 | 0 |
| 2024-03-14 | Mehta Vimal (CEO and President) | Option Ex | 2,610 | .00 | 0 |
| 2024-03-14 | Yocca Frank (Chief Scientific Officer) | Option Ex | 521 | .00 | 0 |
| 2024-03-14 | O'neill Vincent (See Remarks) | Option Ex | 521 | .00 | 0 |
| 2024-03-14 | Steinhart Richard I (Chief Financial Officer) | Option Ex | 521 | .00 | 0 |
| 2023-12-14 | Rodriguez Javier (See Remarks) | Option Ex | 521 | .00 | 0 |
| 2023-12-14 | Mehta Vimal (CEO and President) | Option Ex | 2,609 | .00 | 0 |
| 2023-12-14 | Yocca Frank (Chief Scientific Officer) | Option Ex | 521 | .00 | 0 |
| 2023-12-14 | O'neill Vincent (Chief Medical Officer) | Option Ex | 521 | .00 | 0 |
| 2023-12-14 | Steinhart Richard I (Chief Financial Officer) | Option Ex | 521 | .00 | 0 |
| 2023-09-14 | Rodriguez Javier (See Remarks) | Option Ex | 521 | .00 | 0 |
| 2023-09-14 | Mehta Vimal (CEO and President) | Option Ex | 2,610 | .00 | 0 |
| 2023-09-14 | Yocca Frank (Chief Scientific Officer) | Option Ex | 521 | .00 | 0 |
| 2023-09-14 | O'neill Vincent (Chief Medical Officer) | Option Ex | 521 | .00 | 0 |
| 2023-09-14 | Steinhart Richard I (Chief Financial Officer) | Option Ex | 521 | .00 | 0 |
| 2023-06-16 | Mehta Vimal (CEO and President) | Sale | 30,000 | 20.93 | 627,990 |
| 2023-06-16 | Mehta Vimal (CEO and President) | Option Ex | 30,000 | .41 | 12,300 |
| 2023-06-15 | Mehta Vimal (CEO and President) | Sale | 30,000 | 21.66 | 649,650 |
| 2023-06-15 | Mehta Vimal (CEO and President) | Option Ex | 30,000 | .41 | 12,300 |
| 2023-06-14 | Rodriguez Javier (See Remarks) | Option Ex | 521 | .00 | 0 |
| 2023-06-14 | Mehta Vimal (CEO and President) | Option Ex | 2,609 | .00 | 0 |
| 2023-06-14 | Yocca Frank (Chief Scientific Officer) | Option Ex | 521 | .00 | 0 |
| 2023-06-14 | O'neill Vincent (Chief Medical Officer) | Option Ex | 521 | .00 | 0 |
| 2023-06-14 | Steinhart Richard I (Chief Financial Officer) | Option Ex | 521 | .00 | 0 |
| 2023-05-22 | Mehta Vimal (CEO and President) | Sale | 6,500 | 25.79 | 167,641 |
| 2023-05-15 | Rodriguez Javier (See Remarks) | Sale | 1,785 | 27.32 | 48,764 |
| 2023-05-15 | Steinhart Richard I (Chief Financial Officer) | Sale | 5,000 | 27.17 | 135,865 |
| 2023-05-14 | Rodriguez Javier (See Remarks) | Option Ex | 5,000 | .00 | 0 |
| 2023-05-14 | Mehta Vimal (CEO and President) | Option Ex | 15,000 | .00 | 0 |
| 2023-05-14 | Steinhart Richard I (Chief Financial Officer) | Option Ex | 5,000 | .00 | 0 |
| 2023-04-06 | Nandabalan Krishnan | Sale | 60,000 | 17.32 | 1,039,200 |
| 2023-04-06 | Nandabalan Krishnan | Option Ex | 60,000 | .41 | 24,600 |
| 2023-03-21 | Mehta Vimal (CEO and President) | Sale | 30,000 | 19.93 | 597,750 |
| 2023-03-21 | Mehta Vimal (CEO and President) | Option Ex | 30,000 | .41 | 12,300 |
| 2023-03-20 | Mehta Vimal (CEO and President) | Sale | 34,500 | 18.54 | 639,630 |
| 2023-03-20 | Mehta Vimal (CEO and President) | Option Ex | 30,000 | .41 | 12,300 |
| 2023-03-15 | Rodriguez Javier (See Remarks) | Sale | 950 | 19.62 | 18,643 |
| 2023-03-15 | Yocca Frank (Chief Scientific Officer) | Sale | 985 | 19.69 | 19,395 |
| 2023-03-15 | O'neill Vincent (Chief Medical Officer) | Sale | 845 | 19.70 | 16,642 |
| 2023-03-15 | Steinhart Richard I (Chief Financial Officer) | Sale | 2,084 | 19.50 | 40,638 |
| 2023-03-14 | Rodriguez Javier (See Remarks) | Option Ex | 2,084 | .00 | 0 |
| 2023-03-14 | Mehta Vimal (CEO and President) | Option Ex | 10,437 | .00 | 0 |
| 2023-03-14 | Yocca Frank (Chief Scientific Officer) | Option Ex | 2,084 | .00 | 0 |
| 2023-03-14 | O'neill Vincent (Chief Medical Officer) | Option Ex | 2,084 | .00 | 0 |
| 2023-03-14 | Steinhart Richard I (Chief Financial Officer) | Option Ex | 2,084 | .00 | 0 |
| 2023-01-20 | Yocca Frank (Chief Scientific Officer) | Sale | 50,000 | 30.00 | 1,500,000 |
| 2023-01-20 | O'neill Vincent (Chief Medical Officer) | Sale | 29,713 | 30.00 | 891,390 |
| 2023-01-20 | O'neill Vincent (Chief Medical Officer) | Option Ex | 29,713 | .41 | 12,182 |
| 2023-01-05 | Nandabalan Krishnan | Sale | 25,889 | 22.62 | 585,738 |
| 2023-01-05 | Nandabalan Krishnan | Option Ex | 25,889 | .41 | 10,614 |
| 2023-01-04 | Nandabalan Krishnan | Sale | 34,111 | 21.90 | 747,030 |
| 2023-01-04 | Nandabalan Krishnan | Option Ex | 34,111 | .41 | 13,985 |
| 2022-12-16 | Mehta Vimal (CEO and President) | Sale | 30,000 | 19.57 | 586,950 |
| 2022-12-16 | Mehta Vimal (CEO and President) | Option Ex | 30,000 | .41 | 12,300 |
| 2022-12-15 | Mehta Vimal (CEO and President) | Sale | 30,000 | 20.02 | 600,750 |
| 2022-12-15 | Mehta Vimal (CEO and President) | Option Ex | 30,000 | .41 | 12,300 |
| 2022-11-11 | Nandabalan Krishnan | Sale | 32,550 | 15.00 | 488,250 |
| 2022-11-11 | Nandabalan Krishnan | Option Ex | 32,550 | .41 | 13,345 |
| 2022-11-10 | Nandabalan Krishnan | Sale | 27,450 | 15.00 | 411,750 |
| 2022-11-10 | Nandabalan Krishnan | Option Ex | 27,450 | .41 | 11,254 |
| 2021-06-25 | Bioxcel Holdings, Inc. | Sale | 473,250 | 30.83 | 14,589,351 |
| 2021-06-25 | Nandabalan Krishnan | Sale | 473,250 | 30.83 | 14,589,351 |
| 2021-06-25 | Mehta Vimal (CEO, President and Secretary) | Sale | 473,250 | 30.83 | 14,589,351 |
| 2021-06-25 | Bioxcel Llc | Sale | 473,250 | 30.83 | 14,589,351 |
| 2021-03-15 | Yocca Frank (Chief Scientific Officer) | Sale | 15,000 | 48.88 | 733,275 |
| 2021-02-17 | O'neill Vincent (Chief Medical Officer) | Sale | 25,000 | 55.51 | 1,387,700 |
| 2021-02-17 | O'neill Vincent (Chief Medical Officer) | Option Ex | 25,000 | 5.71 | 142,625 |
| 2021-02-16 | Yocca Frank (Chief Scientific Officer) | Sale | 15,000 | 58.53 | 877,950 |
| 2021-02-01 | Steinhart Richard I (Chief Financial Officer) | Sale | 3,750 | 48.15 | 180,562 |
| 2021-02-01 | Steinhart Richard I (Chief Financial Officer) | Option Ex | 3,750 | 5.55 | 20,812 |
| 2021-01-25 | Yocca Frank (Chief Scientific Officer) | Sale | 15,000 | 48.08 | 721,125 |
| 2021-01-25 | Yocca Frank (Chief Scientific Officer) | Option Ex | 15,000 | .41 | 6,150 |
| 2021-01-19 | O'neill Vincent (Chief Medical Officer) | Sale | 25,000 | 50.40 | 1,259,900 |
| 2021-01-19 | O'neill Vincent (Chief Medical Officer) | Option Ex | 25,000 | .41 | 10,250 |
| 2020-12-28 | O'neill Vincent (Chief Medical Officer) | Sale | 25,000 | 52.19 | 1,304,625 |
| 2020-12-28 | O'neill Vincent (Chief Medical Officer) | Option Ex | 25,000 | .41 | 10,250 |
| 2020-02-14 | Yocca Frank (Chief Scientific Officer) | Option Ex | 80,000 | .41 | 32,800 |
| 2019-08-23 | Mueller Peter (Director) | Buy | 1,554 | 9.34 | 14,514 |
| 2019-08-22 | Mueller Peter (Director) | Buy | 6,646 | 8.83 | 58,684 |
| 2019-08-21 | Mueller Peter (Director) | Buy | 1,800 | 8.42 | 15,156 |
| 2019-08-16 | Mehta Vimal (CEO, President and Secretary) | Buy | 974 | 8.89 | 8,658 |
| 2019-08-15 | Mehta Vimal (CEO, President & Secretary) | Buy | 2,625 | 8.67 | 22,758 |
| 2019-08-14 | Mehta Vimal (CEO, President & Secretary) | Buy | 358 | 8.44 | 3,021 |
| 2019-08-13 | Mehta Vimal (CEO, President & Secretary) | Buy | 1,000 | 8.75 | 8,750 |
| 2018-12-14 | Mehta Vimal (CEO, President, Secretary) | Buy | 2,000 | 4.41 | 8,824 |
| 2018-12-07 | Mueller Peter (Director) | Buy | 7,400 | 5.00 | 37,037 |
| 2018-12-06 | Mueller Peter (Director) | Buy | 1,395 | 5.00 | 6,981 |
| 2018-12-04 | Mehta Vimal (CEO, President, Secretary) | Buy | 1,000 | 5.12 | 5,120 |
| 2018-12-04 | Yocca Frank (Chief Scientific Officer) | Buy | 450 | 5.20 | 2,338 |
| 2018-12-04 | Mueller Peter (Director) | Buy | 4,007 | 5.12 | 20,515 |
| 2018-12-03 | Mehta Vimal (CEO, President, Secretary) | Buy | 1,000 | 5.15 | 5,150 |
| 2018-12-03 | Yocca Frank (Chief Scientific Officer) | Buy | 450 | 5.23 | 2,353 |
| 2018-12-03 | Steinhart Richard I (Chief Financial Officer) | Buy | 500 | 5.20 | 2,600 |
| 2018-11-30 | Mehta Vimal (CEO, President, Secretary) | Buy | 1,000 | 5.12 | 5,115 |
| 2018-11-30 | Yocca Frank (Chief Scientific Officer) | Buy | 450 | 5.20 | 2,339 |
| 2018-11-30 | Steinhart Richard I (Chief Financial Officer) | Buy | 500 | 5.00 | 2,500 |
| 2018-11-29 | Nandabalan Krishnan (Director) | Buy | 1,000 | 4.92 | 4,915 |
| 2018-11-29 | Yocca Frank (Chief Scientific Officer) | Buy | 500 | 5.02 | 2,511 |
| 2018-11-29 | Steinhart Richard I (Chief Financial Officer) | Buy | 500 | 5.00 | 2,500 |
Insider trading activities including stock purchases, stock sales, and option exercises of BTAI listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Bioxcel Therapeutics, Inc. (symbol BTAI, CIK number 1720893) see the Securities and Exchange Commission (SEC) website.